Statements

October 2022

October 4, 2022 10/4/2022 Takeda to Discontinue Manufacturing of NATPAR® / NATPARA® for Patients with Hypoparathyroidism at the End of 2024

March 2022

March 22, 2022 3/22/2022 Takeda Provides NATPARA U.S. Regulatory Update

October 2021

October 28, 2021 10/28/2021 Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

April 2021

April 20, 2021 4/20/2021 Pausing to Acknowledge

September 2020

September 1, 2020 9/1/2020 Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

November 2014

November 5, 2014 11/5/2014 Takeda Update Regarding Colcrys® Litigation

October 2014

October 27, 2014 10/27/2014 Takeda Responds to Ruling in Diabetes Drug Case Expresses Continued Confidence in ACTOS

September 2014

September 3, 2014 9/3/2014 Takeda Responds to Judgment in Diabetes Drug Case Takeda Stresses Continued Confidence in ACTOS

April 2014

April 8, 2014 4/8/2014 Takeda Responds to Verdict in Diabetes Drug Case